Larimar Therapeutics (LRMR)
(Delayed Data from NSDQ)
$3.74 USD
+0.43 (12.99%)
Updated Aug 5, 2025 04:00 PM ET
2-Buy of 5 2
D Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LRMR 3.74 +0.43(12.99%)
Will LRMR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LRMR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LRMR
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
LRMR: What are Zacks experts saying now?
Zacks Private Portfolio Services
SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance
5 Small Drug Stocks to Buy as Trump Gets Re-Elected
Other News for LRMR
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and ...
LRMR Stock Priced at Lower End of Predetermined Range
Larimar Therapeutics 18.75M share Spot Secondary priced at $3.20
Larimar Therapeutics Announces Pricing of Underwritten Public Offering | LRMR Stock News
Larimar Therapeutics prices $60M stock offering